One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response

被引:58
作者
Faber, L.
Welge, D.
Fassbender, D.
Schmidt, H. K.
Horstkotte, D.
Seggewiss, H.
机构
[1] Ruhr Univ Bochum, Heart & Diabetes Ctr, Dept Cardiol, D-32545 Bad Oeynhausen, Germany
[2] Leopoldina Hosp, D-97422 Schweinfurt, Germany
关键词
hypertrophic obstructive cardiomyopathy; percutaneous septal ablation; left ventricular outflow tract gradient; myocardial contrast echocardiography;
D O I
10.1007/s00392-007-0578-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim The aim of this study was to analyze hemodynamic and clinical outcome in a cohort of 312 patients who were followed up over a period of 12 months after alcohol septal ablation (PTSMA) for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). Methods and results PTSMA was intended in 337 patients with HOCM (mean age: 54 +/- 15 years), with 312 procedures completed by injection of 2.8 +/- 1.2 ml of alcohol. In 25 patients (8%) the intervention was aborted, mostly because of contrast echocardiographic findings. In the 312 patients who received alcohol, permanent pacing was necessary in 22 cases (7%); and in-hospital mortality was 1.3% (four patients). During follow-up, contact to six patients (2%) was lost, and three additional patients (1%) died. The 299 patients who either underwent non-invasive reassessment in our institution or transmitted follow-up data from their local physician formed the study population. Improvement in symptoms was reported by 272 patients (91%). Mean NYHA functional class was reduced from 2.9 +/- 0.4 to 1.5 +/- 0.7 (p < 0.0001) along with a gradient reduction (echo-Doppler) from 59 +/- 32 to 8 +/- 15 mmHg at rest, and from 120 +/- 42 to 28 +/- 32 mmHg with provocation (p < 0.0001 each). Exercise capacity improved from 94 +/- 51 to 119 +/- 40 watts (p = 0.001), and peak oxygen consumption from 18 +/- 4 to 21 +/- 6 ml/kg/min (p = 0.01). Younger age and higher outflow gradients at baseline and immediately after intervention were associated with a less favorable hemodynamic outcome. The degree of limitation of exercise capacity at baseline was the only predictor of symptomatic improvement. Conclusions Catheter-based septal ablation is an effective non-surgical technique for reducing symptoms and outflow gradients in HOCM. In contrast to a previous study, in this cohort of 312 patients there was no association between post-interventional enzyme release and hemodynamic success. Younger patients with high baseline gradients, however, tended to have a less favorable hemodynamic outcome with higher residual gradients.
引用
收藏
页码:864 / 873
页数:10
相关论文
共 33 条
[11]   Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH) - Catheter interventional treatment for hypertrophic obstructive cardiomyopathy [J].
Gietzen, FH ;
Leuner, CJ ;
Raute-Kreinsen, U ;
Dellmann, A ;
Hegselmann, J ;
Strunk-Mueller, C ;
Kuhn, HJ .
EUROPEAN HEART JOURNAL, 1999, 20 (18) :1342-1354
[12]   SURGICAL-MANAGEMENT OF HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY - EARLY AND LATE RESULTS [J].
HERIC, B ;
LYTLE, BW ;
MILLER, DP ;
ROSENKRANZ, ER ;
LEVER, HM ;
COSGROVE, DM .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (01) :195-208
[13]   Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy [J].
Kimmelstiel, CD ;
Maron, BJ .
CIRCULATION, 2004, 109 (04) :452-456
[14]   Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy - Outcome in the first series of patients [J].
Knight, C ;
Kurbaan, AS ;
Seggewiss, H ;
Henein, M ;
Gunning, M ;
Harrington, D ;
Fassbender, D ;
Gleichmann, U ;
Sigwart, U .
CIRCULATION, 1997, 95 (08) :2075-2081
[15]  
Kuhn H, 2004, Z KARDIOL, V93, P23, DOI 10.1007/s00392-004-1028-6
[16]  
Kuhn H, 1997, EUR HEART J, V18, P846
[17]   Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy [J].
Lakkis, NM ;
Nagueh, SF ;
Kleiman, NS ;
Killip, D ;
He, ZX ;
Verani, MS ;
Roberts, R ;
Spencer, WH .
CIRCULATION, 1998, 98 (17) :1750-1755
[18]   Clinical course of hypertrophic cardiomyopathy with survival to advanced age [J].
Maron, BJ ;
Casey, SA ;
Hauser, RG ;
Aeppli, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (05) :882-888
[19]   Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy - A randomized, double-blind, crossover study (M-PATHY) [J].
Maron, BJ ;
Nishimura, RA ;
McKenna, WJ ;
Rakowski, H ;
Josephson, ME ;
Kieval, RS .
CIRCULATION, 1999, 99 (22) :2927-2933
[20]   Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy [J].
Nagueh, SF ;
Ommen, SR ;
Lakkis, NM ;
Killip, D ;
Zoghbi, WA ;
Schaff, HV ;
Danielson, GK ;
Quiñones, MA ;
Tajik, AJ ;
Spencer, WH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (06) :1701-1706